Evidence map›Paper›PMID 41516937›Full record

ReviewHealthcare (Basel, Switzerland)2025

Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events.

Yasser Ali Khoshaim, Yahya Z Habis, Afnan Ghazi Daqnah, Razan Khalid Alqurashi, Yazeed Shaker Abdulrahim, Abdullah Sakkat, Sultan Ali Alsubhi, Deema Tawfeq Almuwlad, Halah Samer Bukhari, Abdulrhman J Shogdar and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yasser Ali KhoshaimDepartment of Internal Medicine, King Abdullah Medical Complex, Jeddah 23816, Saudi Arabia.
Yahya Z HabisDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-8042-6428
Afnan Ghazi DaqnahEast Jeddah General Hospital, Jeddah 22253, Saudi Arabia.
Razan Khalid AlqurashiHome Health Care Center, Jeddah First Health Cluster, Jeddah 22233, Saudi Arabia.
Yazeed Shaker AbdulrahimEast Jeddah General Hospital, Jeddah 22253, Saudi Arabia.
Abdullah SakkatDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Sultan Ali AlsubhiFaculty of Medicine, King Abdulaziz University, Rabigh 21589, Saudi Arabia.
Deema Tawfeq AlmuwladFaculty of Medicine, Umm Al-Qura University, Mecca 24381, Saudi Arabia.
Halah Samer BukhariFaculty of Medicine, Umm Al-Qura University, Mecca 24381, Saudi Arabia.
Abdulrhman J ShogdarFaculty of Medicine, King Abdulaziz University, Rabigh 21589, Saudi Arabia.ORCID 0009-0006-6718-677X
Omar Ashraf AmirHome Health Care, King Abdullah Medical Complex, Jeddah 23816, Saudi Arabia.
Mohamed Sayed ZaazoueeFaculty of Medicine, Al-Azhar University, Assiut 71524, Egypt.ORCID 0000-0003-0904-9153

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Crohn’s diseasefilgotinibJAK1 inhibitornetwork meta-analysissystematic review

Identifiers

PMID41516937
PMCPMC12785585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.